The 2020 Capital Market Open Day of China Re Group was held in Beijing on 22 December. The event focused on the hot topic of “health insurance” and presented the latest updates and development strategy of China Re Group’s life and health reinsurance protection business. He Chunlei, President of China Re Group, Tian Meipan, Chief Actuary, Li Ming, Business Director, Liu Shukai, Director of the Board Office, Zhang Xiaodong, founder and CEO of the strategic partner of China Re Life, and Guo Weichao, founder and CEO of Insure123.cn, attended the event.

　　President He Chunlei first expressed his gratitude to the investors and analysts who participated in the open day. He said that, under the prevailing circumstances, driven by both the policy and the market, China’s commercial health insurance has ushered in new development opportunities. In the course of high-quality transformation and development of the health insurance market, China Re Group has always played an indispensable role as the main channel for China’s reinsurance industry. Looking ahead, China Re Group will continue to provide stable underwriting capacity, product technical support and infrastructure for the insurance industry by leveraging its professional technological strength, long-term extensive database, deep insight in domestic risks and solid customer relationship so as to contribute professional value to the “Healthy China” strategy. Meanwhile, China Re Group, as the largest reinsurer in the domestic health insurance market, will accelerate the development of the new “China Re Life + N” health insurance development ecosystem and fully share the benefits of the fast-growing industry, thus creating greater value for shareholders and society.

　　Tian Meipan delivered a keynote speech on the health insurance market in China and the health insurance development strategy of China Re Group. Tian Meipan pointed out that, in the face of China’s fast-growing health insurance market with great potential, China Re Group has been unswervingly committed to the core position of protection-type business, and firmly determined health insurance as the main strategy of protection-type business. With respect to product innovation, it will strengthen the supply-side reform and provide comprehensive product development solutions tailored for new demands and new economy. With respect to data construction, China Re Group will consolidate the database and promoted multi-scenario applications in various areas from strengthening data governance, historical weaknesses, data mining, data friends circle to data applications. With respect to industry integration, China Re Group will integrate medical, pharmaceutical, health management and other fields by capitalizing on strategic investment and innovative payment so as to achieve a win-win situation.

　　In the subsequent round table forum and Q&A session, Tian Meipan, Chief Actuary of China Re Group, Li Ming, Business Director, and Zhang Chu, assistant to the general manager of the actuarial department of China Re Life, together with two special guests, discussed the new trend of the integration of commercial health insurance and health industry, shared the latest cooperation progress on industry integration between China Re Group and MediTrust Health, and made professional responses to the business model and future prospects of special drug insurance, the risk management measures of special drug insurance in the area of high-frequency medical service, the breakthrough of sales of the commercial health insurance channel, etc., which further deepened the understanding of investors and analysts on the development and investment value of the Company’s life and health reinsurance business.

　　As the only Hong Kong listed reinsurance group, China Re Group attaches great importance to the interaction with the capital market. The event was the last of the investor relations events for the year, which clearly demonstrated the Company’s remarkable development results and investment value, and was of positive significance to further enhance the Company’s influence in the capital market and boost investors’ confidence. More than 60 domestic and overseas institutions including Morgan Stanley, Goldman Sachs and CICC attended the teleconference, and nearly a thousand people watched the live meeting. After the event, Morgan Stanley, Citibank and Huatai Financial all issued research reports to acknowledge the health insurance development strategy and future development potential of the Company.